22 citations
,
March 2017 in “Transplant Infectious Disease” Leflunomide successfully treated a rare skin condition in a liver transplant patient.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
April 2021 in “Bioscientia Medicina Journal of Biomedicine and Translational Research” Patients with lupus nephritis and COVID-19 can improve with proper treatment.
Isotretinoin effectively improved severe pityriasis rubra pilaris with complications.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
10 citations
,
September 2014 in “European Journal of Dermatology” A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
1 citations
,
March 2023 in “Journal of the American College of Cardiology” May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
March 2002 in “Clin-Alert” In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.
5 citations
,
November 2010 in “Veterinary Record” The monkeys' skin infection was cured in eight weeks using oral terbinafine, topical washes, and disinfectant fogging.
1 citations
,
August 2024 in “British Journal of Dermatology” Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
12 citations
,
November 2014 in “Journal of Cutaneous Medicine and Surgery” Antiviral medication valganciclovir may improve skin and hair in Trichodysplasia Spinulosa patients.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
3 citations
,
February 2010 in “Clinical kidney journal” Combining ciclosporin and simvastatin can cause severe kidney damage.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
11 citations
,
August 1988 in “PubMed” Interferon therapy is a promising and safe treatment for hepatitis B in Southeast Asia.
11 citations
,
January 1998 in “Dermatology” Isotretinoin effectively treated severe acne in HIV-positive women, with improved skin and CD4 counts, but some experienced side effects like skin dryness and hair loss.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
November 2024 in “Rheumatology Advances in Practice” Visceral leishmaniasis can mimic rheumatoid arthritis symptoms, especially in immunocompromised patients.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
4 citations
,
October 2018 in “JAMA Dermatology” Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.